Proteins present in the blood may be able to predict a person's risk of developing cancer more than seven years before they are diagnosed with the disease, according to new research.
Oxford BioDynamics (OBD) and King’s College London (KCL) have partnered to use OBD’s EpiSwitch technology to identify patients at risk of rheumatoid arthritis (RA) who can benefit from abatacept treatment.
Closed Loop Medicine, a techbio company specializing in personalized drug-plus-software therapies, and Pharmanovia, a global pharmaceutical firm known for rejuvenating established medicines, have initiated their OptiZest study.
Abzena, an end-to-end CDMO for biologics and bioconjugates, will be presenting its latest AbZelect and AbZelectPRO cell line development (CLD) platforms and more at BIO 2024.
Daniel Spurgin, director of strategic partnerships at ReciBioPharm, unveiled the company's BIO 2024 plans and how the CDMO is set to flourish as more viral and nucleic acid therapeutics move to the clinic in the next two years.
Life sciences business Cytiva is set to launch its new platform, designed to accelerate the manufacturing process for autologous CAR-T cell therapies. Find out more about the company's priorities, market challenges, expansion plans and more.
Ahead of Bio 2024, we caught up with Matt Cokely, global technical consultant strategic leader, and Helen Gates, marketing director, at Ecolab Life Sciences to find out what the company is planning for the event and how it is navigating current challenges...
Before the industry is set to arrive in San Diego for Bio International 2024, we spoke with Dr. Harald Oberegger, global head business development at Novartis Contract Manufacturing. At the event, the company will be showcasing its cutting-edge technologies,...
Hazel Jones is the interim CEO and chief operations officer at Enhanc3D Genomics. We sat down with her to discuss her leap of faith into 3D genomics, and how she is scaling the business and driving operational change.
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people irrespective of the amount of weight they lose while using the medication, according to a new study.
Alchemab Therapeutics, an antibody discovery firm known for identifying natural antibodies in disease-resistant individuals, has published a peer-reviewed article titled "Predictability of B cell clonal persistence and immunosurveillance in breast...
Regeneron Pharmaceuticals’ gene therapy for otoferlin-related hearing loss, a genetic cause of deafness, has restored hearing to normal levels in one deaf child within just 24 weeks.
Circio, a biotech firm specializing in circular RNA-based gene therapy, has unveiled two posters showcasing in vivo proof-of-concept for its circVec platform at ASGCT 2024.
Calliditas Therapeutics has announced encouraging data from its proof-of-concept phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN).
The Asia-Pacific (APAC) region is leading the way in the asthma clinical trials space, conducting the most studies globally between 2019-2023, with China, India, and South Korea among the top countries, GlobalData reveals.
Courtney Noah works in scientific affairs at BioIVT and after an amazing biology teacher in grade nine gave her a passion for science, she then followed the same teacher through her education.
We sat down with Jay Ferguson, director at Houlihan Lokey's Healthcare Group, to discuss why he views the pharma services sector as a highly promising investment opportunity. He outlines his prediction that a confluence of tailwinds is set to sustain...
Broken String Biosciences, a genomics company driving cell and gene therapy developing, has entered a research collaboration with the Francis Crick Institute, a biomedical discovery institute dedicated to understanding the biology underlying health and...
Adare Pharma Solutions, a tech driven CDMO specializing in oral dosage forms, has announced expansions of its high potency handling capabilities in the U.S. and Europe.
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, have garnered a lot of attention in the pharma industry and beyond.
Renée Aguiar-Lucander, CEO of Calliditas, is driving the advancement and launch of TARPEYO – the company’s medication targeting rare disease IgA nephropathy. We spoke with Renée about her journey from investment banking to science and the joy of bringing...
